The study suggested that pathway-based biomarker signatures derived from on-treatment tumor specimens compared to pretreatment tumor specimens were better predictors of response to anti-PD1 therapies in metastatic melanoma patients. The gene discussed is PDCD1; the disease is metastatic melanoma.